Brief: Immunome Announces Initiation Of Phase 1B Study Of Imm-Bcp-01 For The Treatment Of Covid-19
09/06/2022 13:04
June 9 (Reuters) - Immunome Inc IMNM.O :
* IMMUNOME ANNOUNCES INITIATION OF PHASE 1B STUDY OF
IMM-BCP-01
FOR THE TREATMENT OF COVID-19
* IMMUNOME INC - TOPLINE DATA IS EXPECTED IN SECOND HALF OF
THIS
YEAR, WHICH IS AN UPDATE FROM OUR PRIOR GUIDANCE
Source text for Eikon: ID:nBwbzTfjWa
Further company coverage: IMNM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage